Drug Profile
Nesvacumab
Alternative Names: Ang2 antibody - Regeneron Pharmaceuticals; REGN-910; SAR-307746Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Regeneron Pharmaceuticals; sanofi-aventis
- Developer Regeneron Pharmaceuticals; Sanofi
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action Angiogenesis inhibitors; Angiopoietin-2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 31 Dec 2014 Discontinued - Phase-I for Solid tumours (Combination therapy) in Canada (IV) before December 2014 (Regeneron, Form 10-K, February 2015)
- 31 Dec 2014 Discontinued - Phase-I for Solid tumours (Combination therapy) in USA (IV) before December 2014 (Regeneron, Form 10-K, February 2015)
- 31 Dec 2014 Discontinued - Phase-I for Solid tumours in Canada (IV) before December 2014 (Regeneron, Form 10-K, February 2015)